|
Vinorelbine-based salvage treatments |
||
| Type |
Number |
%* |
|
|
||
| Vinorelbine alone |
16 |
23 |
| Vinorelbine + T |
32 |
46 |
| Vinorelbine + Infusional 5-FU or Capecitabine |
8 |
11 |
| Vinorelbine + Infusional 5-FU or Capecitabine + T |
3 |
4 |
| Vinorelbine + Gemcitabine |
8 |
11 |
| Vinorelbine + other agents** |
3 |
4 |
|
Legend: T, trastuzumab *Because of rounding sum of percentages does not equal 0. **1 patients in this group received also trastuzumab | ||
Montemurro et al. BMC Cancer 2008 8:209 doi:10.1186/1471-2407-8-209 |
||